UCB announced plans to buy Neurona Therapeutics in a deal valued at $650 million, with up to $500 million in milestone payments, to broaden its clinical-stage epilepsy portfolio. The transaction is designed to add an additional pipeline platform as UCB works to expand beyond its current neurology footprint. For Neurona, the acquisition provides scale and resources to advance its epilepsy assets through clinical development. For UCB, the move signals prioritization of late-stage and clinical-stage opportunities rather than relying solely on internal discovery. The reported structure—sizeable upfront consideration plus milestone-linked payments—reflects expectations for meaningful development progress tied to clinical and regulatory milestones.